GENFIT, a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and liver diseases, and LabCorp®, a leading global life sciences company that is focused on advancing health and guiding patient care decisions, have agreed to a five-year exclusive licensing agreement for GENFIT’s NIS4™ technology to help identify patients with at-risk non-alcoholic steatohepatitis (NASH). As part of the agreement, LabCorp will develop and commercialize

Read more...

Heron Therapeutics, Inc., a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, announced that the European Commission has granted a marketing authorization for ZYNRELEF (formerly known as HTX-011) for the treatment of somatic postoperative pain from small- to medium-sized surgical wounds in adults. The marketing authorization follows the European Medicines Agency

Read more...

Ahead of the CPhI Festival of Pharma (5-16 October, 2020) – global pharma’s largest ever virtual gathering – the CPhI Pharma Index[i] shows only Italy and India have improved their score in 2020, with the majority of industry executives looking for new supply chain partners. The Index – an aggregated confidence score across the five main small molecule categories in each of the largest economies – compiles the findings from more than 550 executives and

Read more...

Syntegon Technology’s Schiedam site is celebrating over half a century of market presence. In October, the company’s Dutch site turns 60. Today a market-leading provider of horizontal flow wrappers, infeed and distribution systems, the current Syntegon Packaging Technology B.V. took up business as Tevopharm, an acronym of Techniek for Voeding and Pharmacie (Technical solutions for food and pharma) in the early 1960s. “We are proud of this long legacy,” Neil Fowell, gen

Read more...

Gilead Sciences, Inc. and Eisai Co., Ltd. announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has granted Gilead K.K. (Tokyo, Japan) regulatory approval of Jyseleca (filgotinib 200 mg and 100 mg tablets), a once-daily, oral, JAK1 preferential inhibitor for the treatment of rheumatoid arthritis (RA) in patients who have had an inadequate response to conventional therapies, including the prevention of structural joint damage. Gilead Japan will hold the marketing

Read more...

Apollomics, Inc., an innovative biopharmaceutical company committed to the discovery and development of mono- and combination- oncology therapies, announced APL-106 (uproleselan) has received Investigational New Drug (IND) approval from the China National Medical Products Administration (NMPA) Center for Drug Evaluation (CDE). This approval enables the initiation of a Phase 1 pharmacokinetics (PK) and tolerability study and includes acceptance of a Phase 3 bridging study of APL-106 in combina

Read more...

Grand River Aseptic Manufacturing ("GRAM"), a leading injectable contract development and manufacturing organization (CDMO), has entered into an agreement with Janssen Pharmaceuticals, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, to support the manufacture of its SARS-CoV-2 vaccine candidate. The agreement includes the technical transfer and fill and finish manufacture of Johnson & Johnson's SARS-CoV-2 vaccine candidate. Together, tea

Read more...

ONCOtracker, Inc and The Binding Site Group Ltd announced they have entered into an exclusive global license and collaboration agreement to develop a novel clinical laboratory test for measuring sBCMA, which has shown promise to monitor and predict outcomes for patients with common blood-based cancers including multiple myeloma (MM) and chronic lymphocytic leukemia (CLL) and other related conditions. sBCMA was first discovered in 2011 by Dr. James Berenson and colleagues at The Inst

Read more...